Nicole Shonka, MD
Associate Professor, Internal Medicine
Division of Oncology & Hematology
Academic Office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 68198-6840
Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fax. 402-559-6520
Practice locations:
Fred & Pamela Buffett Cancer Center
505 S. 45th Street
Omaha, NE 68105 (map)
Cancer Center at Village Pointe
111 North 175th Street
Omaha, NE 68118 (map)
Education:
University of Nebraska Medical Center, Resident, (2002-2005)
University of Nebraska Medical Center, Fellow, (2007-2009)
University of Texas MD Anderson Cancer Center, Fellow (2009-2010)
Hospital Appointments:
Nebraska Medicine
Interests:
Research in novel therapies for primary tumors of the brain and spine, secondary brain tumors, and leptomeningeal disease
Biographical Sketch:
Dr. Shonka is an Assistant Professor in the Oncology/Hematology Division in the Department of Internal Medicine at UNMC. Dr. Shonka received her medical education at UNMC and did her residency and general oncology fellowship at UNMC as well. She then went to the University of Texas' MD Anderson Cancer Center where she completed an additional Neuro-oncology fellowship and returned to Nebraska as faculty in July 2010. She is currently the only fellowship-trained Neuro-oncologist in the state of Nebraska. She currently serves on the editorial board for Targeted Oncology, is an expert reviewer for the Journal of Neuro-Oncology, and is a member of the national Disease-Focused Expert Panel on Brain Tumors for the Veterans' Administration Medical Center.
Publications:
Shonka NA. Targets for therapy in ependymoma. Targeted Oncology. 6 : 163-169. 2011
Tsung AJ, Prabhu SS, Lei X, Chern JJ, Benjamin Bekele N, Shonka NA. Cerebellar glioblastoma: A retrospective review of 21 patients at a single institution. Journal of Neuro-Oncology. 105 : 555-562. 2011
Shonka N, Brandes A, De Groot JF. Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology (Williston Park, N.Y.). 26 : 1083-91. 2012
Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 8 : 117-25. 2013
Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, Gilbert MR. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: A retrospective review within the era of temozolomide. Journal of Neuro-Oncology. 113 : 305-11. 2013
Bhatt VR; Aryal, MR; Karmacharya P; Shonka N. Simple partial status epilepticus presenting as left sided hemiparesis. Austin Journal of Clinical Case Reports. 2014 May
Bhatt VR; Shrestha R; Shonka N; Bociek RG. Near misdiagnosis of glioblastoma as primary central nervous system lymphoma. Journal of Clinical Medicine Research. 2014 Aug; Vol. 6 (4): p. 299-301
Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 12 : 1517-23. 2014
Shonka NA, Kessinger AM, Aizenberg MR. Intrathecal interleukin-2 for melanomatous meningitis. J. Clin. Oncol. 32 : e111-3. 2014
Webre C; Shonka N; Smith L; Liu D; de Groot J. PC or PCV; That is the question: primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine. Anticancer research. 2015; 0250-7005
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed